EGFR and non-small cell lung carcinoma: Mao et al. (2017) reported in a meta-analysis of 15 studies a pooled sensitivity of peripheral blood in detecting EGFR mutation status in advanced NSCLC patients of 0.69 (95% CI: 0.59–0.78) and a pooled specificity of 0.97 (95% CI: 0.94–0.99), with a summary receiver operating characteristic curve of 0.93 (95% CI: 0.91–0.95) [99].